Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Towa Pharmaceutical Co., Ltd.

Capitalization 200B 1.25B 1.1B 990M 947M 1.72B 116B 1.79B 11.83B 4.69B 55.4B 4.7B 4.61B P/E ratio 2026 *
10.1x
P/E ratio 2027 * 10x
Enterprise value 375B 2.35B 2.06B 1.86B 1.78B 3.23B 218B 3.36B 22.2B 8.8B 104B 8.83B 8.64B EV / Sales 2026 *
1.35x
EV / Sales 2027 * 1.23x
Free-Float
47.41%
Yield 2026 *
1.91%
Yield 2027 * 2.03%
02-13 Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
01-21 Towa Pharmaceutical Concludes A Basic Agreement with Otsuka Pharmaceutical to Establish A Collaborative Framework for Pharmaceutical Manufacturing CI
01-21 Towa Pharmaceutical, Otsuka Agree on Manufacturing Tie-Up to Secure Drug Supply MT
01-21 Towa Pharmaceutical Co Ltd - Notice of conclusion of a basic agreement with Otsuka Pharmaceutical to establish a collaborative framework for pharmaceutical manufacturing RE
11-10 Towa Pharmaceutical Co., Ltd. Announces Cash Dividend for the Second Quarter-End of Fiscal Year Ending March 31, 2026, Payable on December 1, 2025 CI
06/08/25 Towa Pharmaceutical Says Yamagata Plant Fire Caused by Static Electricity MT
16/07/25 Japanese Shares End Marginally Lower Despite Improving July Business Sentiment MT
16/07/25 Towa Pharmaceutical Reports No Injuries in Yamagata Plant Fire, Operations Resuming MT
15/07/25 Japanese Shares Rise Ahead of Tokyo Trade Talks With US MT
15/07/25 Towa Pharmaceutical Reports Fire at Yamagata Plant; No Injuries MT
25/06/25 Towa Pharmaceutical Co., Ltd. Appoints Osamu Uchikawa as Executive Managing Director from Prior Role of Director, Effective June 25, 2025 CI
15/05/25 Towa Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2025 and Full Year Ending March 31, 2026 CI
15/05/25 Towa Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Fiscal Year Ending March 31, 2026 CI
1 day-1.09%
1 week-1.33%
Current month-7.82%
1 month-0.61%
3 months+13.71%
6 months+36.78%
Current year+11.68%
1 week 4,025
Extreme 4025
4,415
1 month 3,965
Extreme 3965
4,445
Current year 3,465
Extreme 3465
4,445
1 year 2,298
Extreme 2298
4,445
3 years 1,703
Extreme 1703
4,445
5 years 1,703
Extreme 1703
4,445
10 years 1,193.33
Extreme 1193.3333
4,445
Manager TitleAgeSince
President 74 31/05/1996
Chief Administrative Officer - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 74 30/11/1983
Director/Board Member 77 31/05/2015
Director/Board Member 71 26/06/2017
Change 5d. change 1-year change 3-years change Capi.($)
-1.09%-1.33%+47.28%+117.96% 1.27B
-0.22%-2.47%+19.24%+198.45% 880B
+0.62%+0.56%+49.80%+58.37% 582B
+0.89%-2.49%+3.41%+42.81% 388B
+0.16%-2.71%+3.95%+23.77% 324B
+0.15%-0.03%+21.29%+33.71% 295B
+0.35%-2.49%+23.91%+58.70% 293B
+0.54%-1.42%+21.79%+7.55% 286B
+0.19%-2.38%+16.02%+56.88% 197B
+0.09%-1.05%+29.25%+81.71% 180B
Average +0.15%-1.54%+23.60%+67.99% 342.74B
Weighted average by Cap. +0.26%-1.37%+22.33%+84.13%

Financials

2026 *2027 *
Net sales 278B 1.74B 1.52B 1.37B 1.32B 2.39B 161B 2.49B 16.42B 6.51B 76.93B 6.53B 6.39B 297B 1.86B 1.62B 1.47B 1.4B 2.55B 172B 2.65B 17.53B 6.95B 82.09B 6.97B 6.82B
Net income 20.02B 125M 110M 99.07M 94.77M 172M 11.6B 179M 1.18B 469M 5.54B 471M 461M 20.2B 127M 111M 99.96M 95.62M 174M 11.71B 181M 1.19B 473M 5.59B 475M 465M
Net Debt 175B 1.1B 961M 868M 830M 1.51B 102B 1.57B 10.37B 4.11B 48.56B 4.12B 4.04B 164B 1.03B 897M 810M 775M 1.41B 94.89B 1.47B 9.68B 3.84B 45.33B 3.85B 3.77B
Logo Towa Pharmaceutical Co., Ltd.
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
Employees
4,788
Date Price Change Volume
16/03/26 4,065.00 ¥ -1.09% 92,700
13/03/26 4,110.00 ¥ 0.00% 93,400
12/03/26 4,110.00 ¥ -3.52% 127,400
11/03/26 4,260.00 ¥ +2.16% 113,400
10/03/26 4,170.00 ¥ +1.21% 104,900
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4,110.00JPY
Average target price
4,680.00JPY
Spread / Average Target
+13.87%

Quarterly revenue - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW